Annualized recurring revenue (“ARR”) of $840 million, an increase of 4% year-over-yearFull-year revenue of $844 million, up 9% year-over-year; ...
Ascendis Pharma (ASND) announced that its board of directors has authorized the company to use approximately $25M to fund a share repurchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback